Excellence in Scientific Discovery

The Institute's comprehensive investigations extend from the earliest phase of basic discovery to the development of new cancer diagnostics, treatment protocols and prevention strategies

Research Programs

Basic, clinical and translational studies into the biology of cancer and the factors that contribute to its onset and growth.


Shared Resources

The most sophisticated technologies and research protocols are offered to SCI members through a number of core facilities.


Key Initiatives

Inter-disciplinary teams of collaborative investigators partner to foster discovery, application and translation of scientific knowledge.


Institute Membership

Scientists and physicians from a wide range of disciplines, all dedicated to reducing the burden of cancer.


News & Publications

Publications, press releases and news are shared with scientists, physicians, patients and friends of the Institute.


Funding Opportunities

Internal and external sources of support for both established cancer research programs and promising new ideas.  


Clinical Trial Support

The Cancer Clinical Trials Office provides regulatory and administrative services to SCI members conducting clinical trials.  


Training Opportunities

Education and professional development designed to train the next generation of cancer researchers and physicians.



National Cancer Institute Designation

News & Publications

  • New guidelines suggested for liver cancer

    A Stanford Medicine study identifies an easily measured biophysical property that can identify Type 2 diabetics at increased risk for liver cancer who don’t meet current screening guidelines.

  • Screening, treatment halve breast cancer deaths

    Treatment of metastatic disease is responsible for nearly one-third of the decrease in annual deaths from breast cancer from 1975 to 2019, according to a Stanford Medicine-led study.

  • Tumor DNA levels in blood predict outcome

    Circulating tumor DNA predicts recurrence and splits disease into two subgroups in Stanford Medicine-led study of Hodgkin lymphoma. New drug targets or changes in treatments may reduce toxicity.